Skip to main content

Table 1 Predicted survival with PAH-specific therapy using weighted mean changes from baseline in RCTs.

From: Hemodynamics in pulmonary arterial hypertension (PAH): do they explain long-term clinical outcomes with PAH-specific therapy?

 

Predicted survival*

Treatment

Year 1

Year 2

Year 3

Placebo

0.719

0.600

0.504

Bosentan

0.778

0.677

0.593

Sitaxentan

   

   100 mg

0.758

0.651

0.562

   300 mg

0.757

0.649

0.560

Sildenafil

   

   20 mg

0.752

0.642

0.552

   40 mg

0.756

0.648

0.559

   80 mg

0.771

0.668

0.583

Epoprostenol

0.784

0.686

0.603

Beraprost

0.741

0.629

0.537

Treprostinil

0.761

0.655

0.567

  1. *Based on the NIH Registry equation.
Back to article page

BMC Cardiovascular Disorders

ISSN: 1471-2261

Contact us